Mutual of America Capital Management LLC Has $3.14 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Mutual of America Capital Management LLC boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 22.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,286 shares of the medical equipment provider’s stock after purchasing an additional 7,432 shares during the period. Mutual of America Capital Management LLC’s holdings in Hologic were worth $3,141,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. McGlone Suttner Wealth Management Inc. acquired a new stake in Hologic during the 4th quarter valued at $27,000. Massmutual Trust Co. FSB ADV boosted its position in Hologic by 69.4% in the 4th quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 227 shares during the last quarter. Allworth Financial LP boosted its position in Hologic by 39.3% in the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 179 shares during the last quarter. Mather Group LLC. bought a new position in Hologic in the 1st quarter valued at $48,000. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its position in Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 468 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HOLX shares. Argus increased their price objective on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Evercore ISI decreased their price objective on Hologic from $78.00 to $76.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 2nd. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their price target for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Finally, Stephens started coverage on Hologic in a research report on Thursday, June 27th. They issued an “overweight” rating and a $87.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.55.

Hologic Stock Performance

HOLX stock opened at $76.49 on Friday. The business’s 50-day moving average price is $74.00 and its two-hundred day moving average price is $74.50. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The firm has a market cap of $17.85 billion, a PE ratio of 39.03, a P/E/G ratio of 2.52 and a beta of 0.99. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $82.45.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.06 earnings per share. As a group, research analysts forecast that Hologic, Inc. will post 4.08 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.